(Total Views: 578)
Posted On: 09/26/2017 11:59:11 AM
Post# of 85307
$PSID One of the biggest barriers to delivering rapid diagnosis and care during a biological outbreak is about to be eliminated, said Lyle L. Probst, President, CEO and Founder of PositiveID Corporation’s (PSID) ExcitePCR subsidiary. DELRAY BEACH, Fla., Sept. 19, 2017 (GLOBE NEWSWIRE)
When asked what makes ExcitePCR’s FireflyDX™ technologies different than other pathogen detection solutions, Probst said, “Sample preparation takes place inside our FireflyDX systems, which means our customers can go from sample capture to answer in 30 minutes or less. On top of that, the FireflyDX devices are small, portable PCR-based units which can be used virtually anywhere around the world. These are just some of the things that set our pathogen detection systems apart from other solutions.” Internal Sample Preparation, Small Size and Rapid Results Differentiate the FireflyDX Systems, says Lyle Probst During BioWatch Panel
https://finance.yahoo.com/news/internal-sampl...00072.html
When asked what makes ExcitePCR’s FireflyDX™ technologies different than other pathogen detection solutions, Probst said, “Sample preparation takes place inside our FireflyDX systems, which means our customers can go from sample capture to answer in 30 minutes or less. On top of that, the FireflyDX devices are small, portable PCR-based units which can be used virtually anywhere around the world. These are just some of the things that set our pathogen detection systems apart from other solutions.” Internal Sample Preparation, Small Size and Rapid Results Differentiate the FireflyDX Systems, says Lyle Probst During BioWatch Panel
https://finance.yahoo.com/news/internal-sampl...00072.html
(0)
(0)
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Scroll down for more posts ▼
